Skip to main content
Premium Trial:

Request an Annual Quote

DTRA Awards NanoBiosym $2M Contract to Develop Genomics/Nanotech Dx for Biodefense

NEW YORK (GenomeWeb News) - Nanobiosym, a Massachusetts company that is developing a diagnostic tool that blends nanotechnology and genomics, said on Friday that it has received a $2 million contract from the United States Defense Threat Reduction Agency.
The company plans to use the contract to validate the use of its technology, called Gene-RADAR, which it has been developing with its commercial partner, Nanobiosym Diagnostics.
Nanobiosym describes Gene-RADAR as a "nanotechnology-enabled platform, that can rapidly and accurately detect genetic fingerprints from any biological organism."
The DTRA, a branch of the US Department of Defense, is focused on reducing the threat of biological warfare and bioterrorism
According to its website, Nanobiosym aims to "create breakthrough scientific insights and revolutionary technologies that emerge from the convergence of physics, nanotechnology, and biomedicine."
The company was founded in 2004 and has received funding from the US Defense Advance Research Project Agency, the US Air Force Office of Scientific Research, and the US Department of Energy.
Nanobiosym is also developing Gene-RADAR to "address unmet needs in the developing world, where the lack of basic infrastructure often precludes effective diagnostics," the company said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.